# Kopran share price today (Kopran Ltd, NSE: KOPRAN)

> Kopran share price today: ₹246.16 at the NSE close on 3 November 2026, up 48.9% in a year. Kopran (NSE: KOPRAN) is worth ₹1,190 crore, trades at a P/E of 47.6 and has closed between ₹113.43 and ₹284.53 over the past 52 weeks. > Kopran Ltd's share price has risen faster than its earnings: +48.9% in a year, against −33.3% for earnings per share. KOPRAN · Pharma - API · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/kopran-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting worse, from the last 12 quarters
- Price: ₹246.16 (+48.9% in a year)
- P/E: 47.6× (higher than 98% of the last 11 years)
- Revenue (Jun 2026): ₹154 Cr (+13.9% on a year ago)
- Profit (Jun 2026): ₹6.7 Cr (−10.1% on a year ago)
- Operating margin: 10.3% (−0.2 points on a year ago)
- ROCE: 7%, FY26
- ROIC: 8.1%, against a 12.0% cost of capital: −3.9 points

The main question: the share price moved +48.9% in a year while yearly earnings per share moved −33.3%. The difference came from the market paying a higher multiple. ## What is the Kopran share price today? Kopran Ltd's share price was ₹246.16 at the close on 3 November 2026. It has been rising for 23 weeks. That is 21.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹113 and ₹285, and at that close it sat 78% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 14 weeks in a row. Over the last 11 years the share price moved +372% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Kopran this quarter? 6 points in one quarter. 1. Promoters cut their stake by 2.6 points in one quarter From 44.4% to 41.8% in the September 2026 quarter. ## What are Kopran's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Kopran reported revenue of ₹154 crore, up 13.9% from ₹135 crore a year earlier, and a profit of ₹6.70 crore, down 10.1% from ₹7.45 crore. ### Kopran results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹154 crore | ₹135 crore | +13.9% |
| Profit | ₹6.70 crore | ₹7.45 crore | −10.1% |
| Earnings per share | ₹1.39 | ₹1.54 | −9.7% |
| Operating margin | 10.3% | 10.4% | −0.2 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Kopran share price history? Kopran closed at ₹246.16 on 3 November 2026, up 48.9% from ₹165.37 a year earlier (31 October 2025) and up 10.2% over five years. Its highest weekly close since March 2016 was ₹345.95 on 13 September 2024. ### Kopran share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹246.30 | −0.1% |
| 1 month ago · 1 Oct 2026 | ₹282.05 | −12.7% |
| 6 months ago · 30 Apr 2026 | ₹164.63 | +49.5% |
| 1 year ago · 31 Oct 2025 | ₹165.37 | +48.9% |
| 3 years ago · 3 Nov 2023 | ₹228.55 | +7.7% |
| 5 years ago · 4 Nov 2021 | ₹223.35 | +10.2% |
| 10 years ago · 4 Nov 2016 | ₹54.60 | +350.8% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹52.10 | +372.5% |
| Highest weekly close since March 2016 · 13 Sep 2024 | ₹345.95 | −28.8% |
| Lowest weekly close since March 2016 · 27 Mar 2020 | ₹18.95 | +1,199.0% |
| 52-week high (weekly close) · 25 Sep 2026 | ₹284.53 | −13.5% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹113.43 | +117.0% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (563 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Kopran? 3 Nov 2026: Kopran closed at ₹246.16, down 0.1% on the week and down 12.7% on the month. 11 Aug 2026: ex-date for a dividend of ₹3 a share. ### Earlier

- Results for April to June 2026: Revenue up 13.9% and profit down 10.1% on a year earlier. ## What dividend does Kopran pay? Kopran paid ₹3 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 1.22% at the ₹246.16 close on 3 November 2026. The last was a dividend of ₹3 a share, ex-date 11 August 2026. ### Kopran dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 11 Aug 2026 | ₹3 | Dividend |
| 4 Sep 2025 | ₹3 | Dividend |
| 2 Sep 2024 | ₹3 | Dividend |
| 7 Sep 2023 | ₹3 | Dividend |
| 4 Aug 2022 | ₹3 | Dividend |
| 5 Aug 2021 | ₹1.50 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Kopran Ltd paid out 56% of its profit as dividends in FY26, and it paid a dividend in 6 of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Kopran on? Kopran is on 2 of our India lists: Momentum stocks and Pharma stocks. - [Momentum stocks Market cap cr: 1170.267935578331](https://www.sectoralpha.in/momentum-stocks-india)
- [Pharma stocks Market value (₹ crore): 1170.267935578331](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Kopran profitable? Kopran Ltd earned ₹6.7 Cr of net profit in the Jun 2026 quarter, −10.1% on the same quarter a year earlier. Full-year FY26 profit was ₹26.0 Cr. Over 10 years profit has grown 9.0% a year on average. That is 4.4% of the quarter's revenue. The same quarter a year earlier earned ₹7.5 Cr. 1 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹26.0 Cr (−33.3% on the year before). Why profit moved: revenue changed +13.9% on a year earlier and the margin moved −0.2 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed −39.9% and revenue +11.1%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Kopran make, and is it growing? Kopran Ltd reported ₹154 Cr of revenue in the Jun 2026 quarter, +13.9% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 10 years it has grown 8.7% a year on average. The last full year, FY26, came in at ₹681 Cr. The last four reported quarters add to ₹700 Cr. FY26 revenue was ₹681 Cr, +8.1% on the year before. Recent pace: the last four quarters grew +11.1% on average, against 8.7% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +12.0%, against +4.8% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −28.4%, against −35.1% a year (accelerating). ## How much of every ₹100 of sales does Kopran keep? Kopran Ltd's operating margin was 10.3% in the Jun 2026 quarter, 0.2 percentage points lower than the same quarter a year ago. Across 13 years it has been between 9.0% and 18.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −0.2 percentage points on the year while gross margin changed +4.0 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Kopran's profit turning into cash? Over the last 3 years, 131% of Kopran Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹67.0 Cr of operating cash against ₹26.0 Cr of profit. After ₹67.0 Cr of spending on assets, ₹0.0 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 131% of profit came in as cash: the cash cycle got 40 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. What to look at next: the bigger use of cash is spending on new assets, at 4.0× depreciation over three years. The next section checks what that spending is building. ## Where does Kopran's cash go? Kopran Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 146 days in FY26, up from 106 days in FY21. It spent ₹182 Cr on assets over the last 3 years. Customers take 141 days to pay, and stock sits for 137 days on average. At FY26 sales of ₹681 Cr, each day of that cycle ties up about ₹1.9 Cr, so roughly ₹272 Cr is tied up in the business at any time. FY26: customers took 141 days to pay and stock sat for 137 days, about 4.5 months of sales sitting as stock, for a full cycle of 146 days, longer than FY21's 106. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 137 days. Customers pay about 141 days after that. Suppliers are paid at 131 days. Together that makes the 146-day cycle. Spending on assets: ₹182 Cr over the last 3 years, against ₹46.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹25.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Kopran's P/E ratio, and how does it compare with its own history? Kopran Ltd's P/E is 47.6×, about the highest it has ever been. Its usual P/E (the middle reading) is 16.4×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −33.3% while the price moved +48.9%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +2.0% a year; about −16.2% a year came from earnings growth and about +18.2 percentage points from the multiple (the market paying more); over 10 years the price moved +16.3% a year; about +4.0% a year came from earnings growth and about +12.3 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Kopran business getting better or worse? Kopran Ltd's business is getting worse. Profit and EPS growth are shrinking: profit growth is −28.4% in the latest quarter, against +160.9% at its best in 12 quarters, with ROCE steady at 8.0%. This is based on 12 quarters of 4 measures. Why it matters: falling lines mean any ratio below that looks low should be read with that direction in mind. ## How much does Kopran earn on its capital? Kopran Ltd earned a ROCE of 7% in FY26. Its return on capital used (ROIC) is 3.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 3.8% net margin and 0.75× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 3.8% net margin × 0.75× asset turnover × 1.71× leverage (assets divided by equity) ≈ 4.9% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 8.1% − 12.0% = −3.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 8.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 6.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Kopran have too much debt? Kopran Ltd has total debt of ₹153 Cr against shareholder equity of ₹530 Cr as of Jun 2026, so its debt is 0.29× its equity, which is very little. Year by year, that ratio went from 0.18 in FY22 to 0.29 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Kopran shareholding pattern? Promoters cut their stake in Kopran Ltd by 2.7 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 41.8% of the company. Foreign institutions moved −0.4 points over the same period, to 0.9%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: −2.7 points over 8 quarters, to 41.8%; Foreign institutions: −0.4 points over 8 quarters, to 0.9%; Domestic institutions: −0.2 points over 8 quarters, to 0.0%. Why the owners changed: promoters drove it (−2.7 points). They reduced their stake. ## How far is Kopran from balance-sheet trouble? For Kopran Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Kopran rank in its industry? 41.5 out of 100, rank 12 of 14 in Pharma - API, with 81% of the evidence available. Kopran Ltd scores 41.5 out of 100 against the 14 companies it is compared with in Pharma - API, ranking 12. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 12.7 + 7.9 + 8.6 + 12.3 = 41.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Kopran compared with? Kopran ranks 12 of 14 Pharma - API companies on the 4-Factor Sector Score, with 41.5 out of 100. 1. [Anuh Pharma Ltd](https://www.sectoralpha.in/stocks/anuh-pharma-ltd) ANUHPHR · breaking out · Evidence leans up · 100% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 6.6% · Profit 23.7% · Operating margin change 3 points · 100% evidence Capital efficiency 13.8/25 · ROCE 14.9% · Operating margin 9% · 100% evidence Valuation 17.8/20 · P/E 18.3× · PEG 0.31 · 100% evidence Relative strength 11.5/20 · Lead over its industry -7.9% · Lead over NIFTY 500 14.5% · 1 year -3.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21.1 + 13.8 + 17.8 + 11.5 = 64.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Senores Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/senores-pharmaceuticals-ltd) SENORES · quiet · Evidence leans up · 75% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.2/35 · Revenue 38.9% · Profit 62.4% · Operating margin change -1 points · 95% evidence Capital efficiency 16.4/25 · ROCE 15.1% · Operating margin 30% · 76% evidence Valuation 9.2/20 · P/E 39.1× · PEG n/a · 15% evidence Relative strength 7.4/20 · Lead over its industry -6.3% · Lead over NIFTY 500 12.6% · 1 year 47% · 100% evidence · 7 of 12 weeks ahead Exact sum: 28.2 + 16.4 + 9.2 + 7.4 = 61.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Innova Captab Ltd](https://www.sectoralpha.in/stocks/innova-captab-ltd) INNOVACAP · leader · Evidence leans up · 96% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 34.4% · Profit 18.5% · Operating margin change 1 points · 88% evidence Capital efficiency 13.0/25 · ROCE 15% · Operating margin 16% · 100% evidence Valuation 7.3/20 · P/E 38.1× · PEG 4.06 · 100% evidence Relative strength 15.8/20 · Lead over its industry 3.4% · Lead over NIFTY 500 25.3% · 1 year 23.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24 + 13 + 7.3 + 15.8 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Beta Drugs Ltd](https://www.sectoralpha.in/stocks/beta-drugs-ltd) BETA · losing its lead · Evidence leans up · 67% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 15.3% · Profit 26.2% · Operating margin change 1 points · 95% evidence Capital efficiency 18.4/25 · ROCE 19.2% · Operating margin 22% · 76% evidence Valuation 8.0/20 · P/E 38.5× · PEG n/a · 50% evidence Relative strength 10.5/20 · Lead over its industry n/a · Lead over NIFTY 500 11.2% · 1 year -3.1% · 25% evidence · 8 of 12 weeks ahead Exact sum: 19.8 + 18.4 + 8 + 10.5 = 56.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Ind-Swift Laboratories Ltd](https://www.sectoralpha.in/stocks/ind-swift-laboratories-ltd) INDSWFTLAB · leader · Evidence leans up · 82% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 29.9% · Profit -64.1% · Operating margin change 14.3 points · 95% evidence Capital efficiency 8.3/25 · ROCE 4.9% · Operating margin 19% · 76% evidence Valuation 7.1/20 · P/E 34.9× · PEG n/a · 50% evidence Relative strength 20.0/20 · Lead over its industry 71.6% · Lead over NIFTY 500 98.2% · 1 year 257.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 8.3 + 7.1 + 20 = 56.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Wanbury Ltd](https://www.sectoralpha.in/stocks/wanbury-ltd) WANBURY · quiet · Evidence leans up · 81% evidence 55.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.0/35 · Revenue 3.6% · Profit 30% · Operating margin change -5.2 points · 88% evidence Capital efficiency 16.6/25 · ROCE 30.7% · Operating margin 9.8% · 100% evidence Valuation 19.2/20 · P/E 11.2× · PEG 0.34 · 100% evidence Relative strength 7.5/20 · Lead over its industry n/a · Lead over NIFTY 500 -19.7% · 1 year -27.9% · 25% evidence · 0 of 12 weeks ahead Exact sum: 12 + 16.6 + 19.2 + 7.5 = 55.3 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 7. [Gujarat Themis Biosyn Ltd](https://www.sectoralpha.in/stocks/gujarat-themis-biosyn-ltd) GUJTHEM · turning · Evidence leans up · 89% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.6/35 · Revenue 16.1% · Profit 6.7% · Operating margin change 9 points · 88% evidence Capital efficiency 18.1/25 · ROCE 18.1% · Operating margin 48% · 100% evidence Valuation 10.3/20 · P/E 97.1× · PEG 1.33 · 65% evidence Relative strength 7.2/20 · Lead over its industry -16.3% · Lead over NIFTY 500 3.7% · 1 year -21.7% · 100% evidence · 5 of 12 weeks ahead Exact sum: 19.6 + 18.1 + 10.3 + 7.2 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Aarti Drugs Ltd](https://www.sectoralpha.in/stocks/aarti-drugs-ltd) AARTIDRUGS · turning · Evidence leans up · 96% evidence 50.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.5/35 · Revenue 10.5% · Profit 1.1% · Operating margin change 1 points · 88% evidence Capital efficiency 13.4/25 · ROCE 12% · Operating margin 14% · 100% evidence Valuation 8.2/20 · P/E 20.6× · PEG 3.2 · 100% evidence Relative strength 12.0/20 · Lead over its industry -6.8% · Lead over NIFTY 500 15.8% · 1 year -11.3% · 100% evidence · 9 of 12 weeks ahead Exact sum: 16.5 + 13.4 + 8.2 + 12 = 50.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Jagsonpal Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jagsonpal-pharmaceuticals-ltd) JAGSNPHARM · breaking out · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 6% · Profit -27% · Operating margin change -1 points · 100% evidence Capital efficiency 19.1/25 · ROCE 22.7% · Operating margin 21% · 100% evidence Valuation 6.4/20 · P/E 30.2× · PEG 3.39 · 100% evidence Relative strength 6.4/20 · Lead over its industry -10.7% · Lead over NIFTY 500 9.9% · 1 year -2.7% · 100% evidence · 7 of 12 weeks ahead Exact sum: 14.6 + 19.1 + 6.4 + 6.4 = 46.5 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 10. [Aarti Pharmalabs Ltd](https://www.sectoralpha.in/stocks/aarti-pharmalabs-ltd) AARTIPHARM · breaking out · Evidence leans down · 85% evidence 44.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 13.4% · Profit 6.7% · Operating margin change 4 points · 100% evidence Capital efficiency 12.4/25 · ROCE 10.7% · Operating margin 22% · 100% evidence Valuation 2.9/20 · P/E 30.4× · PEG 5.52 · 100% evidence Relative strength 11.8/20 · Lead over its industry n/a · Lead over NIFTY 500 22.9% · 1 year 2.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 17.8 + 12.4 + 2.9 + 11.8 = 44.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Fermenta Biotech Ltd](https://www.sectoralpha.in/stocks/fermenta-biotech-ltd) FERMENTA · losing its lead · Evidence leans down · 64% evidence 42.8 out of 100 Growth Capital Valuation Relative
12. Kopran Ltd this page KOPRAN · breaking out · Evidence leans down · 81% evidence 41.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 12.7/35 · Revenue 12% · Profit -28.4% · Operating margin change -0.2 points · 88% evidence Capital efficiency 7.9/25 · ROCE 6.7% · Operating margin 10.3% · 100% evidence Valuation 8.6/20 · P/E 46.2× · PEG 1.01 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 43% · 1 year 44.6% · 25% evidence · 11 of 12 weeks ahead Exact sum: 12.7 + 7.9 + 8.6 + 12.3 = 41.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 13. [Orchid Pharma Ltd](https://www.sectoralpha.in/stocks/orchid-pharma-ltd) ORCHPHARMA · losing its lead · Evidence leans down · 66% evidence 37.8 out of 100 Growth Capital Valuation Relative
14. [Themis Medicare Ltd](https://www.sectoralpha.in/stocks/themis-medicare-ltd) THEMISMED · quiet · Most evidence points down · 71% evidence 30.1 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - API](https://www.sectoralpha.in/sectors/pharma-api), all 14 compared on one page. ## Which companies are close to Kopran in size? Kopran is the 11th largest of 14 Pharma - API companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Beta Drugs, Jagsonpal Pharmaceuticals and Fermenta Biotech. Just below it: Anuh Pharma, Themis Medicare and Wanbury. ### Pharma - API companies close in size

1. [Beta Drugs Ltd](https://www.sectoralpha.in/stocks/beta-drugs-ltd) ₹2,000 crore
2. [Jagsonpal Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jagsonpal-pharmaceuticals-ltd) ₹1,427 crore
3. [Fermenta Biotech Ltd](https://www.sectoralpha.in/stocks/fermenta-biotech-ltd) ₹1,229 crore
4. Kopran Ltd ₹1,155 crore
5. [Anuh Pharma Ltd](https://www.sectoralpha.in/stocks/anuh-pharma-ltd) ₹875 crore
6. [Themis Medicare Ltd](https://www.sectoralpha.in/stocks/themis-medicare-ltd) ₹873 crore
7. [Wanbury Ltd](https://www.sectoralpha.in/stocks/wanbury-ltd) ₹662 crore

[All 14 Pharma - API companies, largest first](https://www.sectoralpha.in/sectors/pharma-api#all-companies)

### Companies close in size in other industries

1. [MMP Industries Ltd](https://www.sectoralpha.in/stocks/mmp-industries-ltd) ₹1,161 crore · Aluminium Products
2. [PVP Ventures Ltd](https://www.sectoralpha.in/stocks/pvp-ventures-ltd) ₹1,157 crore · Realty - Construction & Contracting
3. Kopran Ltd ₹1,155 crore
4. [Nelcast Ltd](https://www.sectoralpha.in/stocks/nelcast-ltd) ₹1,153 crore · Castings, Forgings & Fastners
5. [Airfloa Rail Technology Ltd](https://www.sectoralpha.in/stocks/airfloa-rail-technology-ltd) ₹1,152 crore · Railway Equipment

## What else do people ask about Kopran? ### What is Kopran's share price today? Kopran Ltd's share price is ₹246.16, +48.9% over the past year. The whole company is worth ₹1,190 Cr on the market. In the last 52 weeks it traded between ₹113 to ₹285; today it is 78% of the way up from the low, 21.5% above its 200-day average (as of 3 November 2026). ### What were Kopran's latest quarterly results? Kopran Ltd reported revenue of ₹154 Cr and net profit of ₹6.7 Cr for the Jun 2026 quarter. Revenue rose 13.9% and profit fell 10.1% compared with a year earlier. Earnings per share were ₹1.39. The operating margin was 10.3%, 0.2 percentage points lower than a year earlier (as of 3 November 2026). ### What is Kopran's market cap? Kopran Ltd's market capitalisation is ₹1,190 Cr at a share price of ₹246.16. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Kopran performing? Kopran Ltd's share price has been rising for 23 weeks. In its latest quarter, revenue rose 13.9% and profit fell 10.1% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 14 weeks running (as of 3 November 2026). ### Will Kopran's share price go up? This page does not forecast Kopran Ltd's share price. What it shows instead: the share price is ₹246.16, and it has been rising for 23 weeks. Its P/E of 47.6× is higher than 98% of its own last 11 years (as of 3 November 2026). ### Who owns Kopran? Promoters own 41.8% of Kopran Ltd, foreign institutions 0.9%, domestic institutions 0.0% and the public 57.3% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 2.7 percentage points over 8 quarters (as of 3 November 2026). ### Where is Kopran in its business cycle? Kopran Ltd's FY26 operating margin was 9.0%, against a 13-year range of 9.0% to 18.0%: the low end of its own range, which is often where recoveries start. The latest quarter was 10.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Kopran story? The main question: the share price moved +48.9% in a year while yearly earnings per share moved −33.3%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Kopran a stock worth studying right now? What the numbers show: Kopran Ltd's share price has risen faster than its earnings: +48.9% in a year, against −33.3% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.